Evidence Table 90. KQ2—Continuous data—Ejection fraction

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/. Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 36585 | At high risk for CHD | ACE inhibitors (no description); furosemide; digoxin, also hydralazine and/or nitrates | NR | Coenzyme Q10 | 27 | at 12 wks of treatment | Mean: 31Median SD: 9SE:Lower: Upper: | Mean:5% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 27 | Mean:31Median SD: 9SE:Lower: Upper: | Mean:5Median:SD:P: |